TEVA - Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month | Benzinga
On Wednesday, GSK Plc (NYSE:GSK) announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all its asthma and chronic obstructive pulmonary disease (COPD) medicines.
The program will be implemented by January 1, 2025.
The medicines in scope are Advair Diskus, Advair HFA, Anoro Ellipta, Arnuity Ellipta, Breo Ellipta, Incruse Ellipta, Serevent Diskus, Trelegy Ellipta, Ventolin HFA.
GSK recently reduced the wholesale acquisition cost for Advair Diskus by an average of 50% and Advair HFA by an average of 20%.
Earlier this week, AstraZeneca Plc (NASDAQ:AZN) announced that starting June 1, 2024, eligible patients will pay no more than $35 per month for ...